Literature DB >> 8530713

Pharmacokinetic and pharmacologic variation between different estrogen products.

M B O'Connell1.   

Abstract

Due to the complex nature of endogenous and exogenous hormone concentration, formation, and metabolism and assay complexity, the pharmacokinetics of estrogen are difficult to study. Oral estrogens have minimal systemic bioavailability (2% to 10%) due to gut and liver (first-pass) metabolism. High concentrations of estrone are achieved with oral administration, whereas higher concentrations of estradiol are generally achieved after percutaneous absorption. Although vaginal products (such as gel, rings, etc.) are administered locally, they achieve high serum concentrations. Estradiol and estrone concentrations and estradiol-to-estrone ratios vary with different estrogen therapies. Approximately 95% to 98% of estradiol is bound loosely to albumin or tightly to sex hormone binding globulin, the major binding protein. The terminal half lives for the different estrogen compounds (after oral or intravenous administration) vary from 1-12 hours. Some conversion rates have been calculated between estrogen and its metabolites. Smoking decreases achievable estrogen concentrations, and has a greater effect on oral products. Oral contraceptives have been found to decrease antipyrine clearance. In the one study evaluating conjugated estrogens, antipyrine clearance was not altered. Oral contraceptives have a variable effect on the elimination of medications. Acetaminophen clearance is increased, whereas clearance of some benzodiazepines, caffeine,and prednisolone is decreased. Phenytoin increases the metabolism of conjugated estrogens. The various estrogen products may produce different clinical effects based on composition. The metabolites (minor components) of conjugated estrogens have been found to have significant effects on lipid concentrations, uterine weight, liver generated compounds, and bone resorption. Because transdermal products bypass the first-pass effect, delayed or decreased effects on lipid profiles and liver generated compounds have been observed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8530713     DOI: 10.1002/j.1552-4604.1995.tb04143.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  25 in total

1.  Self-reported changes in providers' hormone therapy prescribing and counseling practices after the Women's Health Initiative.

Authors:  Susan L Lakey; Susan D Reed; Andrea Z LaCroix; Lou Grothaus; Katherine M Newton
Journal:  J Womens Health (Larchmt)       Date:  2010-11-09       Impact factor: 2.681

2.  Dairy intake and semen quality among men attending a fertility clinic.

Authors:  Myriam C Afeiche; Naima D Bridges; Paige L Williams; Audrey J Gaskins; Cigdem Tanrikut; John C Petrozza; Russ Hauser; Jorge E Chavarro
Journal:  Fertil Steril       Date:  2014-03-14       Impact factor: 7.329

3.  Pharmacokinetics and systemic endocrine effects of the phyto-oestrogen 8-prenylnaringenin after single oral doses to postmenopausal women.

Authors:  M Rad; M Hümpel; O Schaefer; R C Schoemaker; W-D Schleuning; A F Cohen; J Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

Review 4.  Evaluating the Role of Hormone Therapy in Postmenopausal Women with Alzheimer's Disease.

Authors:  Jelena Osmanovic-Barilar; Melita Salkovic-Petrisi
Journal:  Drugs Aging       Date:  2016-11       Impact factor: 3.923

5.  Effects of Estrogen Replacement on Bone Geometry and Microarchitecture in Adolescent and Young Adult Oligoamenorrheic Athletes: A Randomized Trial.

Authors:  Kathryn E Ackerman; Vibha Singhal; Meghan Slattery; Kamryn T Eddy; Mary L Bouxsein; Hang Lee; Anne Klibanski; Madhusmita Misra
Journal:  J Bone Miner Res       Date:  2019-11-07       Impact factor: 6.741

6.  Sex hormone levels and risk of primary open-angle glaucoma in postmenopausal women.

Authors:  Jae Hee Kang; Bernard A Rosner; Janey L Wiggs; Louis R Pasquale
Journal:  Menopause       Date:  2018-10       Impact factor: 2.953

Review 7.  The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review.

Authors:  Ronald F Zec; Mehul A Trivedi
Journal:  Neuropsychol Rev       Date:  2002-06       Impact factor: 7.444

8.  Tonic Premarin dose-dependently enhances memory, affects neurotrophin protein levels and alters gene expression in middle-aged rats.

Authors:  Elizabeth Engler-Chiurazzi; Candy Tsang; Sean Nonnenmacher; Winnie S Liang; Jason J Corneveaux; Laszlo Prokai; Matthew J Huentelman; Heather A Bimonte-Nelson
Journal:  Neurobiol Aging       Date:  2009-11-02       Impact factor: 4.673

Review 9.  Aromatase inhibitor-associated bone loss: clinical considerations.

Authors:  Shubham Pant; Charles L Shapiro
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Premarin improves memory, prevents scopolamine-induced amnesia and increases number of basal forebrain choline acetyltransferase positive cells in middle-aged surgically menopausal rats.

Authors:  Jazmin I Acosta; Loretta Mayer; Joshua S Talboom; Cynthia Zay; Melissa Scheldrup; Jonathan Castillo; Laurence M Demers; Craig K Enders; Heather A Bimonte-Nelson
Journal:  Horm Behav       Date:  2008-12-03       Impact factor: 3.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.